IDO1 and melanoma: For instance, ECHO-301/KEYNOTE-252 phase 3 trial showed that combining IDO1 inhibitor (Epacadostat) with pembrolizumab did not enhance progression-free survival or overall survival compared to pembrolizumab alone in melanoma patients [310].